JP2008520645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520645A5 JP2008520645A5 JP2007542159A JP2007542159A JP2008520645A5 JP 2008520645 A5 JP2008520645 A5 JP 2008520645A5 JP 2007542159 A JP2007542159 A JP 2007542159A JP 2007542159 A JP2007542159 A JP 2007542159A JP 2008520645 A5 JP2008520645 A5 JP 2008520645A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- trifluoromethyl
- alkoxy
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 48
- 125000005843 halogen group Chemical group 0.000 claims 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 229920001577 copolymer Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- -1 Of B Chemical group 0.000 claims 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 235000019000 fluorine Nutrition 0.000 claims 5
- 229960003512 nicotinic acid Drugs 0.000 claims 5
- 239000011664 nicotinic acid Substances 0.000 claims 5
- 235000001968 nicotinic acid Nutrition 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 229960005370 atorvastatin Drugs 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- TXLPBBOMUYSABG-UHFFFAOYSA-N 1-[3-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-fluorophenyl]ethanone Chemical compound CC(=O)C1=CC=C(F)C(C=2C(=CC(=CC=2)C(F)(F)F)CN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)=C1 TXLPBBOMUYSABG-UHFFFAOYSA-N 0.000 claims 1
- OBZBVYOIXKKXKG-UHFFFAOYSA-N 2-[3-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxyphenyl]acetonitrile Chemical compound COC1=CC=C(CC#N)C=C1C1=CC=C(C(F)(F)F)C=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OBZBVYOIXKKXKG-UHFFFAOYSA-N 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- SRDCONKRNRXDFD-UHFFFAOYSA-N 3-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1C1=CC=C(C(F)(F)F)C=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SRDCONKRNRXDFD-UHFFFAOYSA-N 0.000 claims 1
- QJKUHJVDVWDZLK-UHFFFAOYSA-N 3-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1C1=CC=C(C(F)(F)F)C=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QJKUHJVDVWDZLK-UHFFFAOYSA-N 0.000 claims 1
- 102000018616 Apolipoproteins B Human genes 0.000 claims 1
- 108010027006 Apolipoproteins B Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960003627 gemfibrozil Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- RXCHLDAWZXXJNK-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-n-[[2-(2-methylsulfanylphenyl)-5-(trifluoromethyl)phenyl]methyl]tetrazol-5-amine Chemical compound CSC1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RXCHLDAWZXXJNK-UHFFFAOYSA-N 0.000 claims 1
- GFDBIYSJOFAHLA-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-n-[[2-[2-(trifluoromethoxy)phenyl]-5-(trifluoromethyl)phenyl]methyl]tetrazol-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC=2C(=CC=C(C=2)C(F)(F)F)C=2C(=CC=CC=2)OC(F)(F)F)=N1 GFDBIYSJOFAHLA-UHFFFAOYSA-N 0.000 claims 1
- ZUVZOHUYPUWISX-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-(2,5-dimethoxyphenyl)-5-(trifluoromethyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2)C(F)(F)F)CN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)=C1 ZUVZOHUYPUWISX-UHFFFAOYSA-N 0.000 claims 1
- OQQFIWZXDDWJDC-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-(2-chloro-5-methylphenyl)-5-(trifluoromethyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound CC1=CC=C(Cl)C(C=2C(=CC(=CC=2)C(F)(F)F)CN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)=C1 OQQFIWZXDDWJDC-UHFFFAOYSA-N 0.000 claims 1
- SDJVFZVIUOEKTL-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-(2-fluoro-5-methylphenyl)-5-(trifluoromethyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound CC1=CC=C(F)C(C=2C(=CC(=CC=2)C(F)(F)F)CN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)=C1 SDJVFZVIUOEKTL-UHFFFAOYSA-N 0.000 claims 1
- NYAKIFLJDVZGMQ-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-(2-methoxy-5-methylphenyl)-5-(trifluoromethyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound COC1=CC=C(C)C=C1C1=CC=C(C(F)(F)F)C=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NYAKIFLJDVZGMQ-UHFFFAOYSA-N 0.000 claims 1
- QXLUAMIFPVGZSR-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound COC1=CC=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QXLUAMIFPVGZSR-UHFFFAOYSA-N 0.000 claims 1
- ATLNMVNKNWYFGL-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-(2-methoxy-5-propan-2-ylphenyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound COC1=CC=C(C(C)C)C=C1C1=CC=CC=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ATLNMVNKNWYFGL-UHFFFAOYSA-N 0.000 claims 1
- XHNVBOHJDKMNOH-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-(5-fluoro-2-methoxyphenyl)-5-(trifluoromethyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound COC1=CC=C(F)C=C1C1=CC=C(C(F)(F)F)C=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XHNVBOHJDKMNOH-UHFFFAOYSA-N 0.000 claims 1
- WIAKUCPQRWZJAB-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-5-(trifluoromethyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound C1=C(C=2C(=CC(=CC=2)C(F)(F)F)CN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)C(OC)=CC=C1CN1CCN(C)CC1 WIAKUCPQRWZJAB-UHFFFAOYSA-N 0.000 claims 1
- VERZDMLBNATJKG-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-[[2-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-5-(trifluoromethyl)phenyl]methyl]-2-methyltetrazol-5-amine Chemical compound COC1=CC=C(CN(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VERZDMLBNATJKG-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63043404P | 2004-11-23 | 2004-11-23 | |
| US71561705P | 2005-09-12 | 2005-09-12 | |
| PCT/IB2005/003500 WO2006056854A1 (en) | 2004-11-23 | 2005-11-21 | Dibenzyl amine compounds and derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520645A JP2008520645A (ja) | 2008-06-19 |
| JP2008520645A5 true JP2008520645A5 (https=) | 2009-01-15 |
Family
ID=35828305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007542159A Withdrawn JP2008520645A (ja) | 2004-11-23 | 2005-11-21 | ジベンジルアミン化合物および誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20090239865A1 (https=) |
| EP (1) | EP1817297A1 (https=) |
| JP (1) | JP2008520645A (https=) |
| KR (1) | KR20070069213A (https=) |
| AP (1) | AP2007003980A0 (https=) |
| AR (1) | AR053784A1 (https=) |
| AU (1) | AU2005308584A1 (https=) |
| BR (1) | BRPI0518476A2 (https=) |
| CA (1) | CA2589322A1 (https=) |
| CR (1) | CR9089A (https=) |
| EA (1) | EA200700924A1 (https=) |
| GT (1) | GT200500339A (https=) |
| IL (1) | IL183133A0 (https=) |
| MA (1) | MA29039B1 (https=) |
| MX (1) | MX2007006137A (https=) |
| NL (1) | NL1030486C2 (https=) |
| NO (1) | NO20073025L (https=) |
| PE (1) | PE20061124A1 (https=) |
| TN (1) | TNSN07200A1 (https=) |
| TW (1) | TW200630350A (https=) |
| UY (1) | UY29222A1 (https=) |
| WO (1) | WO2006056854A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006073973A2 (en) | 2004-12-31 | 2006-07-13 | Reddy Us Therapeutics, Inc. | Novel benzylamine derivatives as cetp inhibitors |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| WO2007041494A2 (en) * | 2005-09-30 | 2007-04-12 | Merck & Co., Inc. | Cholesteryl ester transfer protein inhibitors |
| JP4981814B2 (ja) * | 2005-12-28 | 2012-07-25 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 選択的なベンジルアミン誘導体およびコレステロールエステル転写タンパク質抑制剤としてのその有用性 |
| JP2009522224A (ja) * | 2005-12-29 | 2009-06-11 | ノバルティス アクチエンゲゼルシャフト | コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体 |
| UY30117A1 (es) * | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| US7919506B2 (en) * | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| US8383660B2 (en) * | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| WO2007128568A1 (en) | 2006-05-10 | 2007-11-15 | Novartis Ag | Bicyclic derivatives as cetp inhibitors |
| RU2008148600A (ru) * | 2006-05-11 | 2010-06-20 | Новартис АГ (CH) | Производные бензиламина в качестве ингибиторов сетр |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| JP5244095B2 (ja) * | 2007-04-13 | 2013-07-24 | 興和株式会社 | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 |
| JP4846769B2 (ja) * | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4834699B2 (ja) * | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| CA2722582A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf. | Biaryl pde4 inhibitors for treating inflammation |
| KR20100098653A (ko) | 2007-11-21 | 2010-09-08 | 디코드 제네틱스 이에이치에프 | 염증의 치료를 위한 바이아릴 ｐｄｅ４ 억제제 |
| CN101952244B (zh) * | 2008-02-01 | 2014-11-05 | 潘米拉制药公司 | 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂 |
| UA98839C2 (en) * | 2008-02-01 | 2012-06-25 | Панмира Фармасьютикалз, Ллк. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
| EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体アンタゴニスト |
| WO2009145989A2 (en) | 2008-04-02 | 2009-12-03 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (en) * | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| WO2010059838A2 (en) * | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| CN102596902A (zh) | 2009-08-05 | 2012-07-18 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
| CA2782085A1 (en) | 2010-01-06 | 2011-07-14 | Panmira Pharmaceuticals, Llc | Dp2 antagonist and uses thereof |
| RU2013114390A (ru) | 2010-08-31 | 2014-10-10 | СНУ Ар энд ДиБи ФАУНДЕЙШН | Применение фетального репрограммирования посредством ppar-дельта-агониста |
| ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
| US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
| MX352074B (es) | 2011-09-27 | 2017-11-08 | Dr Reddys Laboratories Ltd | Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis. |
| US9717714B2 (en) | 2012-12-19 | 2017-08-01 | Merck Sharp & Dohme Corp. | Spirocyclic CETP inhibitors |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN115677572B (zh) * | 2021-07-29 | 2024-05-28 | 武汉思瓴生物科技有限公司 | 氟代酰胺类衍生物、药物组合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1360172A1 (en) * | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonists |
| JP2003221376A (ja) * | 2001-11-21 | 2003-08-05 | Japan Tobacco Inc | Ｃｅｔｐ活性阻害剤 |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
| CN1942428A (zh) * | 2004-04-13 | 2007-04-04 | 默克公司 | Cetp抑制剂 |
-
2005
- 2005-11-21 PE PE2005001363A patent/PE20061124A1/es not_active Application Discontinuation
- 2005-11-21 JP JP2007542159A patent/JP2008520645A/ja not_active Withdrawn
- 2005-11-21 AP AP2007003980A patent/AP2007003980A0/xx unknown
- 2005-11-21 MX MX2007006137A patent/MX2007006137A/es unknown
- 2005-11-21 EA EA200700924A patent/EA200700924A1/ru unknown
- 2005-11-21 US US11/719,885 patent/US20090239865A1/en not_active Abandoned
- 2005-11-21 AU AU2005308584A patent/AU2005308584A1/en not_active Abandoned
- 2005-11-21 TW TW094140833A patent/TW200630350A/zh unknown
- 2005-11-21 CA CA002589322A patent/CA2589322A1/en not_active Abandoned
- 2005-11-21 AR ARP050104864A patent/AR053784A1/es unknown
- 2005-11-21 EP EP05805656A patent/EP1817297A1/en not_active Withdrawn
- 2005-11-21 WO PCT/IB2005/003500 patent/WO2006056854A1/en not_active Ceased
- 2005-11-21 KR KR1020077011611A patent/KR20070069213A/ko not_active Ceased
- 2005-11-21 BR BRPI0518476-2A patent/BRPI0518476A2/pt not_active Application Discontinuation
- 2005-11-22 NL NL1030486A patent/NL1030486C2/nl not_active IP Right Cessation
- 2005-11-22 UY UY29222A patent/UY29222A1/es not_active Application Discontinuation
- 2005-11-23 GT GT200500339A patent/GT200500339A/es unknown
-
2007
- 2007-04-30 CR CR9089A patent/CR9089A/es not_active Application Discontinuation
- 2007-05-10 IL IL183133A patent/IL183133A0/en unknown
- 2007-05-22 TN TNP2007000200A patent/TNSN07200A1/fr unknown
- 2007-05-23 MA MA29936A patent/MA29039B1/fr unknown
- 2007-06-13 NO NO20073025A patent/NO20073025L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520645A5 (https=) | ||
| CA2645291A1 (en) | Dibenzyl amine derivatives as cetp inhibitors | |
| JP2016503786A5 (https=) | ||
| JP2007525516A5 (https=) | ||
| HRP20241674T1 (hr) | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe | |
| JP2012506896A5 (https=) | ||
| JP2010509379A5 (https=) | ||
| HRP20140346T1 (hr) | DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE | |
| RU2018106914A (ru) | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция | |
| JP2011528362A5 (https=) | ||
| RU2328489C3 (ru) | Кристаллическая форма соли 4-(3-хлор-4-(циклопропиламинокарбонил)аминофенокси)-7-метокси-6-хинолинкарбоксамида или сольвата этой соли и способы ее получения | |
| RU2007115900A (ru) | Производные бензола, имеющие 2 или более заместителей | |
| JP2016516028A5 (https=) | ||
| JP2014518853A5 (https=) | ||
| JP2019537605A5 (https=) | ||
| ZA200403137B (en) | Dibenzylamine compound and medicinal use thereof | |
| JP2010529203A5 (https=) | ||
| JP2013505903A5 (https=) | ||
| JPWO2019013311A5 (https=) | ||
| EP2995610A1 (en) | 4-dedimethylamino tetracycline compounds | |
| JP2004516285A5 (https=) | ||
| JP2011500783A (ja) | ヒストンデアセチラーゼ阻害剤 | |
| JP2006508987A5 (https=) | ||
| HRP20161631T1 (hr) | Dihidropirazolni gpr40 modulatori | |
| RU2015143675A (ru) | Ship1 модуляторы и относящиеся к ним способы |